{"classes":[{"categories":[{"measurements":[{"comment":"Confidence intervals could not be estimated for some arms due to a limited number of events and censoring; therefore, only median duration of stable disease is reported where applicable.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"12.3"},{"comment":"Confidence intervals could not be estimated for some arms due to a limited number of events and censoring; therefore, only median duration of stable disease is reported where applicable.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"12.1"},{"groupId":"OG002","lowerLimit":"12.286","upperLimit":"37.857","value":"20.4"},{"comment":"Upper confidence interval bounds were not estimable in some arms due to censoring","groupId":"OG003","lowerLimit":"13.143","upperLimit":"NA","value":"25.143"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"DoSD was defined as the time from the date of T-cell infusion to the first date of the radiological PD. This analysis of DoSD only applied to participants with BOR as confirmed CR, confirmed PR, or confirmed SD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received afamitresgene autoleucel 0.1x10\\^9 transduced cells","id":"OG000","title":"Afamitresgene Autoleucel, Group 1"},{"description":"Participants who received afamitresgene autoleucel 0.5-1.2x10\\^9 transduced cells","id":"OG001","title":"Afamitresgene Autoleucel, Group 2"},{"description":"Participants who received afamitresgene autoleucel 1.2-10x10\\^9 transduced cells","id":"OG002","title":"Afamitresgene Autoleucel, Group 3 + Expansion"},{"description":"Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.","id":"OG003","title":"Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel","reportingStatus":"POSTED","timeFrame":"From date of afamitresgene autoleucel infusion to first date of radiological PD or censored date","title":"Duration of Stable Disease (DoSD)","type":"SECONDARY","unitOfMeasure":"Weeks"}